+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H1 2020

  • ID: 5017436
  • Drug Pipelines
  • March 2020
  • Region: Global
  • 250 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • BlueWillow Biologics Inc
  • Dnarx LLC
  • i2 Pharmaceuticals Inc
  • PeptiDream Inc
  • Vaccibody AS
  • MORE
Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H1 2020, provides an overview of the Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline landscape.

H1N1 Infection also called as swine flu is a new kind of flu in humans. It's caused by a contagious virus. H1N1 flu infects the breathing tubes in nose, throat, and lungs. The disease is contagious. When people who have it cough or sneeze, they spray tiny drops of the virus into the air. Signs and symptoms include cough, fever, sore throat, stuffy or runny nose, body aches, headache and fatigue. Treatment includes medication (antiviral drugs).

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H1N1 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 7, 9, 4, 43, 7 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 4, 2, 13 and 2 molecules, respectively.

Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H1N1 Subtype Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • BlueWillow Biologics Inc
  • Dnarx LLC
  • i2 Pharmaceuticals Inc
  • PeptiDream Inc
  • Vaccibody AS
  • MORE
  • Introduction
  • Influenza A Virus, H1N1 Subtype Infections - Overview
  • Influenza A Virus, H1N1 Subtype Infections - Therapeutics Development
  • Influenza A Virus, H1N1 Subtype Infections - Therapeutics Assessment
  • Influenza A Virus, H1N1 Subtype Infections - Companies Involved in Therapeutics Development
  • Influenza A Virus, H1N1 Subtype Infections - Drug Profiles
  • Influenza A Virus, H1N1 Subtype Infections - Dormant Projects
  • Influenza A Virus, H1N1 Subtype Infections - Discontinued Products
  • Influenza A Virus, H1N1 Subtype Infections - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by AbbVie Inc, H1 2020
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by Abzyme Therapeutics LLC, H1 2020
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by Adimmune Corp, H1 2020
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by Akshaya Bio Inc, H1 2020
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by Alla Chem LLC, H1 2020
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by Allergy Therapeutics Plc, H1 2020
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by Altimmune Inc, H1 2020
  • Influenza A Virus, H1N1 Subtype Infections - Dormant Projects, H1 2020
  • Influenza A Virus, H1N1 Subtype Infections - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Influenza A Virus, H1N1 Subtype Infections - Dormant Projects, H1 2020 (Contd..2), H1 2020
  • Influenza A Virus, H1N1 Subtype Infections - Dormant Projects, H1 2020 (Contd..3), H1 2020
  • Influenza A Virus, H1N1 Subtype Infections - Dormant Projects, H1 2020 (Contd..4), H1 2020
  • Influenza A Virus, H1N1 Subtype Infections - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AbbVie Inc
  • Abzyme Therapeutics LLC
  • Adimmune Corp
  • Akshaya Bio Inc
  • Alla Chem LLC
  • Allergy Therapeutics Plc
  • Altimmune Inc
  • Ansun Biopharma Inc
  • Asavi Llc
  • AstraZeneca Plc
  • Beijing Minhai Biotechnology Co Ltd
  • BlueWillow Biologics Inc
  • Brandenburg Antiinfektiva GmbH
  • BunyaVax BV
  • CEL-SCI Corp
  • Changchun Bcht Biotechnology Co Ltd
  • Chicago Biosolutions Inc
  • CHO Pharma Inc
  • Cidara Therapeutics Inc
  • Cilian AG
  • Cocrystal Pharma Inc
  • Curevac AG
  • Cytocom Inc
  • Dnarx LLC
  • Emergent BioSolutions Inc
  • Ena Therapeutics Pty Ltd
  • EpiVax Inc
  • Etubics Corp
  • FluGen Inc
  • Gamma Vaccines Pty Ltd
  • Genentech Inc
  • GlaxoSmithKline Plc
  • Greffex Inc
  • i2 Pharmaceuticals Inc
  • ILiAD Biotechnologies LLC
  • Imutex Ltd
  • Inovio Pharmaceuticals Inc
  • InvVax Inc
  • Jiangsu Kanion Pharmaceutical Co Ltd
  • Johnson & Johnson
  • Mayly Life Sciences
  • Medicago Inc
  • Microbiotix Inc
  • NanoViricides Inc
  • New Amsterdam Sciences Inc
  • Novavax Inc
  • PeptiDream Inc
  • Pneumagen Ltd
  • Recce Ltd
  • Sanofi Pasteur SA
  • Sciogen Inc
  • Seqirus Ltd
  • Serum Institute of India Ltd
  • TechnoVax Inc
  • Tiba Biotech LLC
  • Touchlight Genetics Ltd
  • UMN Pharma Inc
  • Vaccibody AS
  • Vacthera BioTech GmbH
  • Vaxart Inc
  • Vaxxas Pty Ltd
  • Viramatix Sdn Bhd
  • Virion Biotherapeutics
  • Vironova Medical AB
  • Virvio Inc
  • Visterra Inc
  • Vivaldi Biosciences Inc
Note: Product cover images may vary from those shown
Adroll
adroll